UBS cuts Neurocrine Biosciences stock price target to $214 on competition
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
More in Finance & Markets
Tech stocks rally as Treasury yields, oil retreat
The Nasdaq gained 0.4% on Tuesday, recovering some ground after a broad selloff sent the Dow down more than 300 points the day before
Rep. James Comer expands House investigation into prediction market insider trading
House Oversight Committee Chair James Comer, R-Ky., announced an expanded investigation into prediction market insider trading.
Australia’s housing market hits a tipping point
Australia’s housing market is facing its biggest decline in more than 40 years, with values already down by 5.9% since April across the five major capitals.